China Pharma Holdings, Inc. Reports Fiscal Year 2018 Financial Results

March 29, 2019 |

10 min read

China Pharma Holdings, Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, announced financial results for the fiscal year ended December 31, 2018.

HAIKOU, China, March 29, 2019 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) (“China Pharma,” the “Company” or “We”), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the fiscal year ended December 31, 2018.

Full Year Highlights

Revenue decreased 6.7% to $12.3 million in fiscal year 2018 from $13.2 million in fiscal year 2017;
Gross margin was 16.0% in fiscal year 2018, compared to 18.7% in fiscal year 2017.
Impairment loss was $6.5 million in fiscal year 2018 compared to $14.2 million in fiscal year 2017, which represented a decrease of $7.7 million;
Loss from operations was $10.4 million in fiscal year 2018 compared to $18.7 million in fiscal year 2017, which represented a decrease of $8.3 million;
Net loss was $10.8 million in fiscal year 2018 compared to $19.3 million in fiscal year 2017. Loss per common share was $(0.25) per basic and diluted share in fiscal year 2018 compared with $(0.44) per basic and diluted share in fiscal year 2017.

In a statement from Ms. Zhilin Li, China Pharma’s Chairman and CEO, “We experienced certain market fluctuations in 2018, but through the continued implementation of sales promotions, our sales revenue of 2018 was comparable to the same period a year ago. Management will continue to vigorously promote sales through active participation in recent provincial market openings to solicit new drug tender offers and allow China Pharma to expand its presence in these markets.” Ms. Li continued, “In addition, we continued experiencing sustained pressure from the more stringent requirements of drug registration standards, consistency evaluations, and the rising costs of clinical trials in 2018. In this challenging environment, the company actively evaluated the technical difficulty, investment demand, time requirements, and investment return rate of all applicable marketed and pipeline products, and actively advanced the compliance process for several key products in 2018.”

Full Year Results

Revenue decreased by 6.7% to $12.3 million for the year ended December 31, 2018, as compared to $13.2 million for the year ended December 31, 2017. This decrease was mainly due to the negative impact associated with health insurance cost controls as well as government policies targeted at reducing drug costs as a proportion of total health-care spending, in conjunction with the Company’s efforts in controlling bad debts by more rigorous screening customers and more stringent policies on payment terms.

Gross profit for the year ended December 31, 2018 was $2.0 million, compared to $2.5 million in 2017. Our gross profit margin in 2018 was 16.0% compared to 18.7% in 2017. This decline in our gross profit margin was mainly due to a decrease in our sales, and our fixed manufacturing overhead.

Our selling expenses for the year ended December 31, 2018 were $3.2 million, a decrease of $0.2 million compared to $3.5 million for the year ended December 31, 2017. Selling expenses accounted for 26.1% of the total revenue in 2018 compared to 26.2% in 2017.

Our general and administrative expenses for the year ended December 31, 2018 were $1.9 million, which was close to $2.0 million in 2017. General and administrative expenses accounted for 15.8% and 15.3% of our total revenues in 2018 and 2017, respectively.

Our bad debt expenses for the year ended December 31, 2018 was $0.6 million, which represented a decrease of $0.8 million compared to $1.4 million in 2017. The decrease in our bad debt expenses was mainly due to the change in the composition of aging of accounts receivables for the years ended December 31, 2018 compared to December 31, 2017, which came in line with the Company’s more stringent scrutiny upon customers’ payment history.

Impairment of intangible assets for the year ended December 31, 2018 was $6.5 million, compared to $14.2 million in 2017. As a pharmaceutical company, we have been focusing on the development and maintenance of our intangible assets, mainly in the form of medical formulas. Because of recently implemented government policies such as consistency evaluations, our management made certain assessments regarding the impairment of our intangible assets as of December 31, 2018 and December 31, 2017 respectively, and identified two formulas and six formulas in 2018 and 2017, respectively, that would likely be unable to generate positive cash flow in the foreseeable future and therefore recognized impairment loss on them accordingly.

Net loss for year ended December 31, 2018 was $10.8 million, or ($0.25) each basic and diluted share, compared to net loss of $19.3 million, or ($0.44) each basic and diluted share, for the year ended December 31, 2017. The decrease in net loss was mainly a result of the decrease in impairment of long term assets.

Financial Condition

As of December 31, 2018, the Company had cash and cash equivalents of $1.2 million compared to $2.0 million as of December 31, 2017. Working capital decreased to ($1.3) million as of December 31, 2018 from $3.1 million as of December 31, 2017.

As of December 31, 2018, our net accounts receivable was $0.9 million, compared to $2.3 million as of December 31, 2017.

For the year ended December 31, 2018, cash flow from operating activities was $1.3 million, as compared to $0.8 million in 2017.

Conference Call

The Company will hold a conference call at 8:30 am E.T. on March 29, 2019 to discuss the results of full year 2018. Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 3784037. A replay of the call will be accessible through April 6, 2019 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 3784037.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focused on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company’s cost-effective, high-margin business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company’s wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company’s filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company’s expectations, except as required by applicable law or regulation.

- FINANCIAL TABLES FOLLOW -

CHINA PHARMA HOLDINGS, INC.
CONSOLIDATED BALANCE SHEETS


	December 31,	December 31,
	2018	2017
ASSETS
Current Assets:
Cash and cash equivalents	$ 1,186,587	$ 2,030,214
Restricted cash	1,273,940	709,796
Banker’s acceptances	20,579	39,867
Trade accounts receivable, less allowance for doubtful
accounts of $17,815,075 and $18,209,734, respectively	916,931	2,293,120
Other receivables, less allowance for doubtful
accounts of $34,884 and $40,010, respectively	170,098	162,981
Advances to suppliers	47	461,307
Inventory	5,054,975	6,407,155
Prepaid expenses	123,759	185,647
Total Current Assets	8,746,916	12,290,087

Advances for purchases of intangible assets	17,069,587	23,722,954
Property, plant and equipment, net	19,294,379	23,541,003
Intangible assets, net	266,443	398,856
TOTAL ASSETS	$ 45,377,325	$ 59,952,900

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Trade accounts payable	$ 1,060,934	$ 1,141,138
Accrued expenses	310,804	276,368
Other payables	3,065,508	2,858,701
Advances from customers	525,647	581,132
Other payables - related parties	1,633,263	1,354,567
Current portion of construction loan facility	2,181,360	2,305,430
Bankers’ acceptance notes payable	1,273,940	709,796
Total Current Liabilities	10,051,456	9,227,132
Non-current Liabilities:
Construction loan facility	4,362,720	6,916,291
Deferred tax liability	764,374	738,175
Total Liabilities	15,178,550	16,881,598
Commitments and Contingencies (Note 12)
Stockholders’ Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized;
no shares issued or outstanding	-	-
Common stock, $0.001 par value; 95,000,000 shares authorized;
43,579,557 shares and 43,579,557 shares outstanding, respectively	43,580	43,580
Additional paid-in capital	23,590,204	23,590,204
Retained (deficit) earnings	(5,270,358)	5,479,809
Accumulated other comprehensive income	11,835,349	13,957,709
Total Stockholders’ Equity	30,198,775	43,071,302
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 45,377,325	$ 59,952,900

CHINA PHARMA HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME (LOSS)


	For the Years
	Ended December 31,
	2018	2017
Revenue	$ 12,330,687	$ 13,212,314
Cost of revenue	10,355,839	10,743,764

Gross profit	1,974,848	2,468,550

Operating expenses:
Selling expenses	3,216,512	3,460,596
General and administrative expenses	1,949,921	2,019,949
Research and development expenses	172,384	90,474
Bad debt expense	604,388	1,393,576
Impairment of long term assets	6,479,057	14,183,969
Total operating expenses	12,422,262	21,148,564

Loss from operations	(10,447,414)	(18,680,014)

Other income (expense):
Interest income	38,516	64,414
Interest expense	(451,258)	(539,334)
Net other expense	(412,742)	(474,920)

Loss before income taxes	(10,860,156)	(19,154,934)
Income tax benefit (expense)	109,989	(122,631)
Net loss	(10,750,167)	(19,277,565)
Other comprehensive income - foreign currency
translation adjustment	(2,122,360)	3,439,733
Comprehensive income (loss)	$ (12,872,527)	$ (15,837,832)
Loss per share:
Basic and diluted	$ (0.25)	$ (0.44)
Weighted average shares outstanding	43,579,557	43,579,557

CHINA PHARMA HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the Years
	Ended December 31,
	2018	2017
Cash Flows from Operating Activities:
Net loss	$ (10,750,167)	$ (19,277,565)
Depreciation and amortization	3,258,739	3,291,330
Inventory write off	954,311	118,003
Bad debt expense	604,388	1,393,576
Deferred income taxes	68,419	122,631
Impairment of long term assets	6,479,057	14,183,969
Changes in assets and liabilities:
Trade accounts and other receivables	99,400	51,024
Advances to suppliers	(449,101)	1,614,958
Inventory	688,852	1,718,336
Trade accounts payable	(16,441)	(2,045,948)
Accrued taxes payable	(147,099)	18,753
Other payables and accrued expenses	437,901	420,523
Advances from customers	(25,127)	(274,068)
Prepaid expenses	53,860	(494,306)
Net Cash Provided by Operating Activities	1,256,992	841,216

Cash Flows from Investing Activities:
Purchases of property and equipment	(51,145)	(136,479)
Net Cash Used in Investing Activities	(51,145)	(136,479)

Cash Flows from Financing Activities:
Payments of construction term loan	(2,263,877)	(1,479,944)
Advances from related party	287,423	-
Net Cash Used in Financing Activities	(1,976,454)	(1,479,944)

Effect of Exchange Rate Changes on Cash	(73,020)	139,619
Net Decrease in Cash and Cash Equivalents	(843,627)	(635,588)
Cash and Cash Equivalents at Beginning of Period	2,030,214	2,665,802
Cash and Cash Equivalents at End of Period	$ 1,186,587	$ 2,030,214

Supplemental Cash Flow Information:
Cash paid for income taxes	$ -	$ -
Cash paid for interest	$ 588,191	$ 525,788

Supplemental Noncash Investing and Financing Activities:
Issuance of banker’s acceptances	$ 625,128	$ 709,796
Accounts receivable collected with banker’s acceptances	579,896	531,294
Inventory purchased with banker’s acceptances	597,686	492,906